Home Mind & Brain New Vaccine, NaeVac, Targets Deadly Brain-Eating Amoeba

New Vaccine, NaeVac, Targets Deadly Brain-Eating Amoeba

Published: Last updated:
Reading Time: 2 minutes

Scientists have achieved a remarkable milestone with the development of NaeVac, a vaccine designed to combat the deadly brain-eating amoeba, Naegleria fowleri. This innovation, which could potentially save countless lives, is especially crucial given the high fatality rate associated with infections caused by this amoeba.

The findings were published in the journal Gene.

Naegleria fowleri, commonly referred to as the brain-eating amoeba, resides in warm freshwater bodies and soil. The amoeba causes primary amoebic meningoencephalitis (PAM), a devastating brain infection, by entering the human body through the nasal mucosa and attacking brain tissues. While PAM is rare, its consequences are dire, with a reported mortality rate between 95 and 99%. The disease is particularly notorious for its rapid progression and devastating impact on the central nervous system.

The creation of NaeVac is a result of exhaustive research led by Ahmet Efe Koseoglu and his team, who utilized in silico methodologies to analyze N. fowleri’s vaccine candidate proteins. This computational approach enabled them to identify three epitopes with high antigenic properties: EAKDSK, LLPHIRILVY, and FYAKLLPHIRILVYS. These epitopes form the foundation of the NaeVac vaccine, combining B-cell, MHC-I, and MHC-II epitopes linked by specific sequences to ensure robust immune response stimulation.

Dr Ahmet Efe Köseoğlu, a researcher from Duisburg-Essen University, shared the study’s motivations and future plans: “Our motivation was to design a specific vaccine against the brain-eating amoeba Naegleria fowleri causing a dangerous and devastating waterborne disease known as primary amoebic meningoencephalitis (PAM) in both humans and animals worldwide.

“After our computational analyses, we discovered three prominent peptides (EAKDSK, LLPHIRILVY, and FYAKLLPHIRILVYS) and designed a potentially highly immunogenic/antigenic multi-epitope peptide vaccine (NaeVac) against the amoeba.

“In the future, we plan to test our designed vaccine in preclinical studies for the development of an approved vaccine and to use our discovered peptides in the development of routine diagnostic tests. Therefore, risk groups, including people drinking contaminated water and swimming in pools and lakes, can be vaccinated and routinely screened all around the world.”

NaeVac’s development is timely, as the incidence of N. fowleri infections has seen an uptick, partly attributed to climate change leading to warmer waters – an ideal environment for the amoeba. Despite the increasing threat, treatment options have been limited, with no FDA-approved vaccines available before NaeVac. The novel vaccine is not only highly antigenic but also non-allergenic and non-toxic, making it a potential game-changer in infectious disease management.

While NaeVac’s in silico results are promising, its journey from a theoretical construct to a practical solution is far from over. The next crucial steps involve synthesising the vaccine in a controlled environment and conducting extensive animal trials to confirm its safety and efficacy. Moreover, understanding the vaccine’s long-term immunogenicity and its effects on various demographic groups will be vital for its successful deployment.

The development of NaeVac has garnered significant interest from the global health community. Its potential to provide a reliable defence against a pathogen with such a high mortality rate offers a beacon of hope. Moreover, this research exemplifies the critical role of computational methods in accelerating vaccine development, especially against emerging pathogens.

© Copyright 2014–2034 Psychreg Ltd